Clinical Study on Tissue Preservation in Breast Augmentation and Reconstruction
← catalyst calendarNCT07623564 · readout in 133 d
Sponsored by Establishment Labs (industry) · ESTA — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
60estimated
Sites
1
Country
Costa Rica
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-01 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Breast Augmentation and Breast Reconstruction
- Mammaplasty
- Breast Augmentation
- Tissue Preservation
Interventions
- Procedure: Mia Harmonization
- Procedure: Mia Scarless Lift
- Procedure: Mia Reconstruction
- Procedure: Joy Dot
- Procedure: Maxtopexia + Mia
Primary outcomes
what the primary-completion date above is the date OFNumber of Adverse Events Related to Tissue Preservation
measured 36 months post-surgery.
Rate of Intraoperative Tissue Integrity Preservation
measured Day of surgery.
Permalink · ESTA's whole pipeline · Catalyst calendar · Every registered study · What changed